Wockhardt drug discovery gets fast track approval by USFDA

Wockhardt today said its new drug discovery programme in anti-infective research has received a major boost after two of its drugs, WCK 771 and WCK 2349, received the Qualified Infectious Disease Product (QIDP)status from the US FDA.

Wockhardt gets USFDA nod for generic Parkinson’s drug

Wockhardt on Tuesday said that it has received US FDA approval for marketing a generic version of extended—release tablets containing Ropinirole hydrochloride.

Wockhardt to launch generic version of Plavix

Wockhardt has received final approval from the United States Food & Drug Administration for marketing tablets of Clopidogrel bisulfate.

Wockhardt gets USFDA nod for generic Aricept tablets

Wockhardt will be launching the product in the US market on May 28, 2011.

Wockhardt gets USFDA nod for generic Aricept tablets

Wockhardt will be launching the product in the US market on May 28, 2011.

Wockhardt gets US nod for Levofloxacin

Pharmaceutical major Wockhardt has received tentative approval from the US Food and Drug Administration (FDA) for marketing Levofloxacin, used for treatment of bacterial infections.

Wockhardt, DBS Bank agree on out-of-court settlement of dispute

Debt-ridden pharmaceutical firm
Wockhardt and DBS Bank have agreed to an out-of-court
settlement of a dispute over loan that the drug manufacturer
had taken from the Singapore-based lender.

Wockhardt gets FDA approval for Nicardipine injections

Pharma company Wockhardt on Wednesday said
it has received the final approval from the US drug regulator
for its anti-hypertensive injection Nicardipine.

Wockhardt gets FDA approval for Nicardipine injections

Drug firm Wockhardt Wednesday said it has received the final approval from the US Food and Drug Administration (FDA) for marketing Nicardipine HCI injections
in 25mg/10 ml strength, used in the treatment of hypertension.

Wockhardt’s consolidated sales grow to Rs 923 cr in Q3

Pharmaceutical and biotechnology major Wockhardt Limited on Tuesday announced a 2.2 percent growth in consolidated sales revenues to stand at Rs 923 crore for the third quarter ended September 30, 2009.

Fortis to buy 10 Wockhardt hospitals for Rs 909 cr

In India`s biggest buyout deal in the
healthcare sector, second largest hospital chain Fortis
Healthcare today said it is acquiring 10 Wockhardt Hospitals
for Rs 909 crore, a move that would narrow down its gap with
market leader Apollo Hospitals.